|
"[A]
method for preventing and fighting the harmful biological effects
of free radicals...namely...inflammation...[and] collagen
degradation"
- U.S. Patent 4,698,360 inventor, Dr. Jack Masquelier.
Flavay™ can have a
dramatic, visible effect on your skin. The nutrients in Flavay™
can be considered as 'collagen vitamins' because they partake in
the biosynthesis of collagen and prevent its destruction. Through
synergistic action with vitamin C, Flavay™ strengthens and
rebuilds the body’s natural collagen proteins and has the
remarkable ability to reactivate damaged collagen and elastin.
Research has demonstrated that Flavay™ binds to collagen fibers
and realigns them to a more youthful, undamaged form. (The same
research also established that common bioflavonoids are completely
inactive in this respect.)
Laboratory
tests
have demonstrated
Flavay’s™ ability to
reduce degradation of elastin fibers by up to
70 percent.
|
Flavay™ improves
the beneficial cross-linking between the amino acids of the fibers
that give skin its flexibility and strength while preventing the
undesirable cross-linking between amino acids that ages skin like
leather. Laboratory tests have demonstrated Flavay’s™
ability to reduce degradation of elastin fibers by up to 70
percent.
Flavay’s™
ability to reactivate damaged collagen and elastin has great
implications for all of your body’s organs. Collagen is required
for the normal functioning of the joints, healthy cartilage and
bones, smooth gliding surfaces, synovial fluid, normal joint
spaces and normal soft tissues surrounding the joints. Collagen is
the building block of connective tissue, veins, arteries,
ligaments and tendons, and every tissue and organ.
Flavay™
Improves Circulation to Skin Cells
Flavay™
strengthens collagen in vessel walls and capillaries—
resulting in radiant and more youthful skin.
|
Improved circulation
is another reason that Flavay™ is an important part of optimally
nourishing your skin. Over 50 years of scientific and clinical
research establishes that Flavay™ actually strengthens collagen
in vascular walls and capillaries (the smallest vessels) by making
the vessels stronger and more elastic. As we age, the tiny
capillaries begin to break down, resulting in diminished blood
flow. Fortifying these tiny blood vessels will improve circulation
throughout the body, including the skin, delivering blood and
nutrients to your skin. Improved circulation results in
well-nourished, healthy skin—which is radiant and more youthful.
Inflammations
and Edema (Swelling)
Flavay™ has been
licensed and sold in France for treating edema and inflammations
since 1950. Puffiness of the eyes and an overall bloated look and
feel are examples of edema. It involves the leakage of blood serum
into surrounding tissues and Flavay™ has shown that it can
reduce this leakage by strengthening capillary walls.
Flavay™
inhibits the release and synthesis of histamine—a key
factor in the promotion of inflammation.
|
One of the very
first benefits observed and studied by the inventor of Flavay™,
Dr. Jack Masquelier, in as early as 1947, was its
anti-inflammatory effect. His and others' research demonstrated
that Flavay™ inhibits the release and synthesis of histamine
(which produces accelerated blood flow, dilates capillaries and
increases their permeability, thereby leaking plasma into
surrounding tissue), a key factor in the promotion of
inflammation. Numerous studies have demonstrated that the
anti-histamine action of Flavay™ is obtained through inhibiting
the activity of the enzyme histidine decarboxylase. Research shows
that Flavay™ may lower the production of histamine with as much
as 86% inhibition of histidine decarboxylase.
In an Australian
study conducted on two groups of soccer players that had sustained
injuries, those that consumed Flavay™ for ten days following
their injuries experienced significantly less swelling than those
who did not and, in some of those taking Flavay™, the swelling
had completely disappeared. Other research has demonstrated the
ways in which Flavay™ may actually inhibit inflammation
including double-blind studies conducted in France which showed
that Flavay™ can reduce postoperative inflammation.
Proven
Safety of Flavay™
After more than 50
years of human use, no adverse effects have been observed.
Furthermore, intensive biological, toxicological, pharmacological
and analytical research was conducted for the purpose of
registering it as a medicine in France and other countries in
Europe. In one study, daily doses of up to 35,000 mg for six
months were determined to cause no adverse effects. Flavay™ was
also clinically tested, in particular for all sorts of symptoms
related to venolymphatic insufficiencies (strenghthening veins,
improving circulation and reducing edema and inflammations). The
spin-off is a goldmine of data: The rigorous testing to meet the
standards required by the health ministries of France, Germany and
other European countries demonstrate that Flavay™ is highly
bioavailable, nontoxic, nonallergenic, noncarcinogenic,
nonmutagenic, will not cause birth defects, and is completely
safe.
Dr. Masquelier’s
unequaled manufacturing process has been conducted for half a
century at the very same facilities in France, and under the
control of French Pharmaceutical inspection. These time-proven
standards serve as a reliable assurance of the quality,
consistency, bioavailability and safety of Flavay™.
Who
can take Flavay™?
Everyone, from the
very young to elderly. Flavay™ has no known contraindications
(conditions under which it should not be used). Flavay™ is
completely safe and nontoxic. In fact, clinical trials have been
conducted in which pregnant women (troubled by varicose veins and
other circulatory problems in the legs) safely used Flavay™.
Why
Trust Flavay™
Consumers need to
know that the marketplace is full of imitations, various “extracts”
and derivative forms of Dr. Masquelier’s scientifically proven
and patented complex. Unfortunately, many have even used Dr.
Masquelier’s name and research in unauthorized ways to promote
illegitimate products.
Flavay™ is the
name you can trust for the precisely defined active polyphenol
complex patented and perfected by the inventor, Dr. Jack
Masquelier, validated by the French Ministry of Health and
documented by a library of research consisting of many patents and
hundreds of scientific papers, articles, doctorate theses,
lectures and presentations. For quality, consistency,
bioavailablity and safety, consumers may rely upon Flavay™.
Flavay™
Improves the Health and Appearance of Skin
Flavay™
is the amazing internal cosmetic, improving the health and
appearance of the skin from the inside out: rebuilding collagen,
improving circulation and health in skin cells, and reducing
inflammation.
CLICK HERE TO SEE WHAT THE CUSTOMERS ARE SAYING
|
|
All About Flavay
| Flavay Plus | What Does
it Do? | Proven Safety
| Directions for Use
Q&A | Comparative Analysis | Endorsements & Testimonials
| How to Purchase
HealthyBodynMind
1-877-352-8042 • (306) 352-8042 • info@healthybodynmind.com
Protected by U.S. PATENT NO. 4,698,360 and international
patents.
Copyright © 1995-2004 Healthy Publisher.
All rights reserved. Healthy Source LLC
|
Statements made herein have not been
evaluated by the Food and Drug Administration. These products are
not intended
to diagnose, treat, cure or prevent any disease.
|
REFERENCES:
Top  |
Masquelier, J. Plant extract with
a proanthocyanidins content as a therapeutic agent having radical scavenging
effect and use thereof. U.S. Patent No. 4,698,360, 1987.
Masquelier, J. A lifetime devoted to OPC and
Pycnogenols. Alfa Omega
Editrice,
Pub., 1996.
Schwitters, B.,
Masquelier, J. OPC in practice. Alfa Omega
Editrice, Publishers,
1995.
Kilham, C., Masquelier, J.
OPC: The miracle antioxidant. Keats Publishing,
Inc., 1997.
Mindell, E., et al. Earl Mindell’s vitamin bible for the 21st century.
Warner Books, Inc., 1999.
Passwater, R.A. The antioxidants: the nutrients that guard your body. Keats
Publishing, Inc., 1985.
Barilla, J. et al. The nutrition superbook: volume 1: the antioxidants.
Keats Publishing, Inc., 1995.
Facino RM, et al. Free radical scavenging action and anti-enzyme activities
of procyanidines from Vitis vinifera. A mechanism for their capillary protective
action. Arzneimittelforschung, 44: 592-601, 1994.
Kuttan R, et al. Collagen treated with catechin becomes resistant to the
action of mammalian collagenase. Experientia, 37: 221-223, 1981.
Masquelier, J., et al. Stabilization du collagene par les oligomeres
procyanidoliques.
Acta Therapeutica, 7:101-105, 1981.
Masquelier, J. Aspects pharmacologiques nouveaux de certains
flavonoides.
A Vie Medical 12:1969.
Laparra, J., et al. Etude pharmaco-cinetique des oligomers procyandoliques
totaux du raisin. Acta Therapeutica, 4, 1978.
Laparra, J., et al. Etude pharmacocinetique des oligomeres
flavonoliques.
Plantes med et phyto, Tome XI, pp. 133-142, 1977.
Robert A.M.; Groult, N.; Six, C.; Robert, L. Etude de l’action des
oligomeres procyanidoliques sur des cellules mesenchymateuses en culture.
Ii l’attachment des fibres elastiques aux cellules. (Study of the effect
of procyanidolic oligomers on mesenchymal cells in culture. Ii attachment
of elastic fibers to the cells.) Pat Biol, (30)6:601-7, 1990.
Porter, Lawrence J., Wong Rosalind Y. Chan, Bock G. The molecular and crystal
structure of (+)-2,3-trans-3,4-trans-leucocyanidin [(2r,3s,+r)-(+)-3,3’,
4.4’, 5.7’-Hexahydroxyflavan] dihydrate, and comparison of its
heterocyclic ring conformation in solution and the solid state. Journal
of the Chemical Society; Perkin Transactions I 1985. pp. 1413-17.
Masquelier, J. Proanthocyanidins et radicaux
libres. 1985.
Uchida, S., et al. Condensed tannins scavenge active oxygen free radicals.
Med Sci Res, (15) 1987. pp. 831-832.
Ariga, T. Radical scavenging action and its mode in procyanidins b-1 and
b-3 from azuki beans to peroxyl radicals. Agric Biol Chem, 54(10) 1990.
pp. 2499-2504.
Da Silva, R., et. al. Radical scavenger capacity of different procyanidins
from grape seeds. Presented at a symposium, “Free radicals in biotechnology
and medicine.” Royal Society Of Chemistry, London January 1990, pp.
79-80.
Bauman, J., Wurm, G., Bruchhausen, F. “Hemmung der prostagladinsynthetase
durch flavonoide und phenolderivate im vergleich nit deren 02 radikalfangereigenschaften”
Arch Pharm, (Weinheim) 313 (1980) pp. 330-337.
Lombard, J., et al. The brain wellness plan. Kensington Pub. Corp., 1998.
Flesch M., et al., Effects of red and white wine on endothelium-dependent
vasorelaxation of rat aorta and human coronary arteries. Am J Physiol 1998;275:1183-94.
Fitzpatrick, D.F., Fleming R.C., Bing B, Maggi DA, O'Malley RM. Isolation
and characterization of endothelium-dependent vasorelaxing compounds from
grape seeds. J Agr & Food Chem In press.
Fitzpatrick, D.F., Maggi D, Bing B, Coffey RG. Vasorelaxation, endothelium,
and wine. BioFactors 1997;6:455-459.
Fitzpatrick, D.F., Hirschfield SL, Ricci T, Jantzen P, Coffey RG. Endothelium-dependent
vasorelaxation caused by various plant extracts. J Cardiovasc Pharmacol
1995;26:90-95.
Fitzpatrick, D.F., Hirschfield SL, Coffey RG. Endothelium-dependent vasorelaxing
activity of wine and other grape products. Amer J Physiol 1993;265:H774-H778.
Lincoln, J., Hoyle, C.H.V., Burnstock, G., Nitric oxide in health and disease.
Cambridge University Press, 1997.
Facino, R.M., et al. Free radical scavenging action and anti-enzyme activities
of procyanidines from vitis vinifera. A mechanism for their capillary protective
action. Arzneimittelforschung, 44: 592-601, 1994.
Kuttan, R., Donnelly,
P.V., Di Ferrante, N. Collagen treated with catechin
becomes resistant to the action of mammalian collagenase. Experientia, 37:
221-223, 1981.
Masquelier, J. Procyanidolic
oligomers. J Parums Cosm
Arom, 95: 89-97, 1990.
Tixier, J.M., et al. Evidence by in vivo and in vitro studies that binding
of pycnogenols to elastin affects its rate of degradation by elastases.
Biochem Pharmacol, 33: 3933-3939, 1984.
Kakegawa, H., et al. Chem.
Pharm. Bull. 33:5079, 1985.
Harmand, M.F.,
Blanquet, P. The fate of total flavanolic oligomers extracted
from ‘vitus vinifera l.’ in the rat. European Journal of Drug
Metabolism and Pharmaccokinetics. 1978, No. 1 pp. 15-30.
Delrieu, P., Ding J.,
Escande, B., Samain, D. Free-radical scavenging activity
of proanthocyanidolic oligomers encapsulated in glycospheres: an in vivo
and in vitro study. Cosmetology Department & S Biovectors, Ramonville
St. Agne France. pp. 1-9.
Meunier, M.T., Villie, F., et al. Inhibition of angiotensin i converting
enzyme by flavanolic compounds: in vitro and in vivo studies. Planta
Medica,
May 26, 1986. pp. 12-15.
Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques
chez l’animal-oedenme de la patte. Sanofi Res Toul Cedex Fr, pp31-40.
Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques
chez l’animal-activite aniagoniste vis-a-vis des mediateurs de l’inflamation.
Sanofi Res Toul Cedex Fr, pp. 31-40.
Dubos, C., Durst, G.,
Hugonot, H. Evolution de la resistance
capillaire,
spontanement ou artificiellement diminuee par l’action d’une substance
capillaro-toxique chez des personnes agees--action benefique d’un agnet
actif sur la micro-circulation: l’Endotelon. Inform. Therapeut. 1980.
pp. 302-305.
Dartenuc, J.Y., et al. Resistance capillaire en geriatrie etude d’un
microangioprotecteur-Endotelon. Bordeaux Med. 13:903-7, 1990.
Lagrue, G., Olivier-Martin, F.,
Grillot, A. “Etude des effets des oligomeres
du procyanidol sur las resistance capillaire dand l’hypertension arterielle
et certaines nephropathies.” Sen. Hosp. Paris 18-25 Septembre, 1981.
Beylot, C., Bioulac, P. Essai therapeutique d’un angioprotecteur
peripherique,
l’Endotelon. Actualite Therapeutique Gaz. Med. de France (87)22:2919-24,
1980.
Lesbre, F.X., Tigaud, J.D. Effect de l’Endotelon sur l’indice
de fragilite capillaire dan une population specifique: les sujets
cirrhotiques. Gaz. Med. de France, (90)24 1983.
Sarrat, L. Abord therapeutique des troubles fonctionnels des membres inferieurs
par un microangioprotecteur l’Endotelon. Bordeaux Med, 11:685-8, 1981.
Delacroix, P. Etude en double aveugle de l’Endotelon dans l’insuffisance
veineuse chronique. Therapeutique, la Revue de Medicine, (27-28) Sept. 1981.
pp. 1793-1802.
Thebaut, J.F, Thebaut, P.,
Vin, F. Etude de l’Endotelon dand les manifestations
fonctionnelles de l’insuffisance veineuse peripherique-resultats d’une
etude en double aveugle portant sur 92 patients.” Gazette Medicale,
(92)1, 1985. pp. 96-100.
Masquelier, J.
Pycnogenols: recent advances in the therapeutical activity
of procyanidins. Supplement of Planta Medica, Journal of Medicinal Plant
Research and Journal of Natural Products, July 1980 pp. 243-256.
Henning, B., et al. Lipid peroxidation and endothelial cell injury: implications
in atherosclerosis. Free Rad Path & Med, (4)1988 pp. 99-106.
Masquelier, J. “Les procyanidols du vin leur role dans l’alcoolisme.”
pp. 88-93.
Gazave, J.M. “Notions recentes sur les capillaires”
unpub. bulletin
from the Laboratoire De Physiologie Patholigie pp. 26-29.
Ruf, J.C. Wine and polyphenols related to platelet aggregation and
atherothrombosis.
Office International Vigne et du Vin, Nutrition and Health Unit, Paris France;
Drugs under Experimental and Clinical Research (Switz.) 25/2-3 (125-131),
1999.
Blaszo, G. Gabor, M.
Oedema-inhibiting effect of
procyanidin. Acta Physiologica
Academiae Scientiarum Hungaricae, Tomus 56(2):235-240, 1980.
Tayau, M.F, LeFevre, G. Action du leucocyanidol sur l’hyalaluronidase.
Bull Soc Pharm Bordeaux, 95:132-136, 1956.
Lamy, M. Utilization des oligomeres procyanidoliques en
gynecologie. Essai
Therapeutique Tomel (14) Sept. 2, 1981. pp. 1021-22.
Henriet, J.P “Une Etude Exemplaire Pour Un
Phlebotrope: l’etude
EIVE.’ Unpub., pp. 77-83.
Pfister, A., Simon,
M.T., Gazave, J.M. Sites de fixation des oligomeres
procyanidoliques dans la paroi des capillaires sanguins du poumon decobaye.
Acta Therapeutica (8) 1982. pp. 223-237.
Kuttan, R., Donnelly, P., Di
Ferrante, N. “Collagen treated with (+)
-catechin becomes resistant to the action of mammalian
collagenase.”
Laboratory of Connective Tissue Research, Dept. of Biochem. Baylor Col.
of Med., Houston TX. 28, May, 1980.
Gendre, P., Laparra, J.,
Barraud, E. “Effect protecteur des oligomeres
procyanidoliques sur le lathyrisme experimental chez le rat.” Ann.
Pharm. Francaises, (43)1, 1985 pp. 61-73.
Corbe, C., Boissin, J.P.,
Siou, A. Light vision and chorioretinal circulation.
Study of the effect of procyanidolic oligomer (Endotelon). Jn. Fr.
Opthalmol,
(11)5:453-460, 1988.
Boissin, J.P., Corbe C.,
Siou, A. Chorioretinal circulation and dazzling:
use of procyanidol oligomers (Endotelon). Bull Soc Ophtalmol Fr, 88(2):173-4,
177-9, 1988.
Proto, F. et al. Electrophysical study of vitis vinifera procyanoside oligomers
effects on retinal function in myopic subjects. Ann Ott Clin Ocul, 114:85-93,
1988.
Saracco, J.B., Estachy,
G.M. Etude d l’Endotelon en
opthalmologie.
Gaz Med de France, 88:2035-2038, 1981.
Scharrer, A., Ober, M. Anthocyanosides in the treatment of retinopathies.
Klin Monatsbl Augenheilkd, 178:386-389, 1981.
Corbe, C., et al. Microangiopathy of the retina. J. Fr.
Opthalmol, 11:453,
1988.
Verin, M.M., Vildy, A.,
Maurin, J.F., Retinopathies et
O.P.C. Bordeaux
Medicale,
(16)11. pp. 1467-74, 1978.
Soyeux, A. et al.
Endotelon. Diabetic retinopathy and
hemorheology. Bull
Soc Ophtalmol Fr. 87(12):1441-4, 1987.
Fromantin, M. “Les oligomeres procyanidoliques dans le traitement de
la fragilite capillaire et de la retinopathie chez les diabetiques. A propos
de 26 cas.” Med Int, 16(11):432-434, Nov. 1981.
Arne, J.L. Contribution a l’etude des oligomeres procyanidoliques:
Endotelon, dans la retinopathie diabetique (a propos de 30 observations).
Gaz. Med. de France, Vol. 89, No. 30, Oct. 8, 1982.
Baruch, J. Effect of Endotelon in postoperative edema. Results of a double-blind
study versus placebo in 32 female patients. Ann Chir Plast Esthet 29(4):393-5,
1984.
Rao, C.N. et al. Influence of bioflavonoids on the collagen metabolism in
rats with adjuvantinduced arthritis. Ital J Biochem. 30:54-62, 1981.
Gabor, M. Pharmacologic effects of flavonoids on blood vessels.
Angiologica,
9:355-374, 1972.
Havsteen, B.
Flavonoids, a class of natural products of high pharmacological
potency. Biochem Pharmacol, 32:1141-48, 1983.
Reimann, H.J., Lorenz, W., Fischer, M., Frölich, R., Meyer, H.J. Berkhauser
Verlag, Vol. 7/1, Univ. of
Marburg/Lahn, Ger., 1977.
Masquelier, J. Action protectrice du vin sur l’ulcere
gastrique. Resultats,
p. 61.
Amella, M., et al. Inhibition of mast cell histamine release by flavonoids
and bioflavonoids. Planta Medica, 5116-20, 1985.
Packer, L., et al. The antioxidant miracle: your complete plan. John Wiley
& Sons, Inc., 1999.
Shaw, R. How [Australian] PycnoGenol [MASQUELIER’s®] Helps Sports
People.
Masquelier, J. Procyanidolic oligomers
(leucocyanidins). Parfums Cosmet
Arom 95:89-97, 1990.
Pecking, A., Desprez-Curely, J.P., Megret, G. Oligomers procyanidoliques (Endotelon) dans le traitement des lymphoedemes
post-therepeutiques de members
superieurs. Symposium Satellite, Congres International d’Angiologie,
Toulouse, France, 4-7 Oct. 1989.
Fahey, T.D., Pearl M. Hormonal effects of phosphatidylserine during 2 weeks
of intense training. Abstract submitted to national meeting of the Amer
College of Sports Medicine, June 1998.
Monteleone, P., Maj, M.,
Beinat, L., Natale, M.,
Kemali, D. Blunting by
chronic phosphatidylserine administration of the stress-induced activation
of the hypothalamo-pituitary-adrenal axis in healthy men. Eur J Clin Pharm
43: 385–388, 1992.
Fahey, T.D., et al. The hormonal and perceptive effects of phosphatidylserine
administration during two weeks of resistive exercise-induced overtraining.
Bio of Sport 15(3):135-44, 1998.
Laparra, J., Michaud, J.
Masquelier, J. Action des oligomeres procyanidoliques
sur le cobaye carence en vitamin c. Tavaux Originaux, University of Bordeaux,
1976.
Masquelier, J. Action comparee de divers facteurs vitaminiques p sur l’oxydation
de l’acide ascorbique par les ions cuivriques. Bull. de la Societe
de Chimie Biologique XXXIII (3-4) 1951. pp. 302-304.
Masquelier, J. Action comparee de divers facteurs vitaminiques p sur l’acide
ascorbique-oxydase. Bull. de la Societe de Chimie Biologique XXXIII (3,4)
1951. pp.304-306
Kakegawa, H., Matsumoto, H., Endo, K., Satoh, T.,
Nonaka, G., Mishioka,
I. “Inhibitory effects of tannins on hyaluronidase activation and on
the degranulation from rat mesentery mast cells.” Chem. Pharm. Bull.
33(11)1985. 5079-5082.
Reiman, H.J., Lorenz, M., Fischer, R.,
Frolich, H., Meyer, J. “Histamine
and acute haemorrhagic lesions in rat gastric mucosa: prevention of stress
ulcer formulation by (+)-catechin, an inhibitor of specific histidine decarboxylase
in vitro.” Dirkhauser Verlag,Vol. 7/1, 1977.
Pariente, J.J.
Parientl-Amsellem, J. “Les oedemes
post-traumatoqies
chez le sportif: essai controle de l’Endothelon.” Actualite Therapeutique
90(3) 2/11 1983 pp. 231-235.
Masquelier, J., et al. “Flavonoids et Pycnogenols” Int J Vit Nut
Res, (49)3:307-311, 1979.
Yu, C. L. et al. Mutagenicity of proanthocyanidins. Food Chem. Toxicol.
25(2):135-9, 1987.
Pantaleoni, G.C.,
Quaglino, D. Univerisity of Aquila Pharmacol-Toxicologica
Report, 1971.
Laparra, J., et al., Acta
Therapeutica, 4:233, 1978.
Volkner, Wolfgang Muller,
Ewald, Micronucleus assay in bone marrow cells
of the mouse with Pycnogenol. Cytotest Cell Research GmbH & Co., projects
143010 & 143021; Feb. 1989.
Acute and chronic toxicity tests. International Bio-Research, Inc., Hanover,
Germany, 1967-1971.
Dumon, M., Michaud, J.,
Masquelier, J. Proanthocyanidin content in vegetable
extracts to be used in the preparation of medicines. Bull. Soc. Pharm. Bordeaux,
129:51-65, 1990.
|
|
